Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma 3Solid Tumor 2Mesothelioma, Malignant 2Uveal Melanoma 1Solid Tumor, Adult 1Recurrence 1MMR-D/MSI-H Colorectal Cancers 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1Advanced Solid Tumor, Adult 1Advanced Solid Tumor 1

Interventions

pembrolizumab 7Radiotherapy 3Proton Therapy 3Interleukin-2 3Cyclophosphamide 3spartalizumab 2fludarabine 2Rosuvastatin Calcium 2Paclitaxel 2Ipilimumab 2Immune Checkpoint Inhibitors 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2toripalimab 1tislelizumab 1sotorasib 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1niraparib 1neotil 1necitumumab 1mirdametinib 1leronlimab 1lenvatinib 1atezolizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor, Adult × niraparib × Other solid neoplasm × Clear all
NCT03209401 2024-02-05

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Georgetown University

Phase 1 Terminated
23 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡